

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of Earliest Event Reported): September 13, 2019**

**CATALYST PHARMACEUTICALS, INC.**  
(Exact Name Of Registrant As Specified In Its Charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-33057**  
(Commission  
File Number)

**76-0837053**  
(I.R.S. Employer  
Identification No.)

**355 Alhambra Circle  
Suite 1250  
Coral Gables, Florida**  
(Address of principal executive offices)

**33134**  
(Zip Code)

**Registrant's telephone number, including area code: (305) 420-3200**

**Not Applicable**  
**Former Name or Former address, if changed since last report**

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Ticker Symbol	Name of Exchange on Which Registered
Common Stock, par value \$0.001 per share	CPRX	NASDAQ Capital Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 8.01 Other Events**

On September 13, 2019, the Company issued a press release announcing that it had determined not to conclude its planned offering of common stock announced on September 11, 2019. The Company believes that the culmination of an offering at the current market price of the common stock is not in the best interest of the Company and its stockholders. A copy of the press release is attached hereto as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

99.1 [Press release issued by the Company on September 13, 2019.](#)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Catalyst Pharmaceuticals, Inc.**

By: /s/ Alicia Grande

\_\_\_\_\_

Alicia Grande

Vice President, Treasurer and CFO

Dated: September 13, 2019

**FOR IMMEDIATE RELEASE****Catalyst Pharmaceuticals, Inc. Determines Not to Proceed with Previously Announced Public Offering of Common Stock**

**CORAL GABLES, Fla., Sept. 13, 2019 (GLOBE NEWSWIRE)** — **Catalyst Pharmaceuticals, Inc.** (NasdaqCM: CPRX) today announced that it will not conclude the offering of shares of its common stock announced on Wednesday, September 11, 2019. The Company believes that the culmination of an offering at the current market price of the common stock is not in the best interest of the Company and its stockholders.

The offering was being made pursuant to an effective shelf registration statement (No. 333-219259) previously filed with the Securities and Exchange Commission.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

**About Catalyst Pharmaceuticals**

Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), anti-MuSK antibody positive myasthenia gravis (MuSK-MG), congenital myasthenic syndromes (CMS), and spinal muscular atrophy (SMA) Type 3. Catalyst's new drug application for Firdapse® (amifampridine) 10 mg tablets for the treatment of adults with LEMS was approved in November 2018 by the U.S. Food & Drug Administration ("FDA"), and Firdapse is now commercially available in the United States. Prior to its approval, Firdapse for LEMS had received breakthrough therapy designation and orphan drug designation from the FDA.

Firdapse is currently being evaluated in clinical trials for the treatment of MuSK-MG, CMS, and SMA Type 3 and has received Orphan Drug Designation from the FDA for myasthenia gravis and CMS. Firdapse (amifampridine) 10 mg tablets is the first and only approved drug in Europe for the symptomatic treatment in adults with LEMS.

Forward-Looking Statements

*This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results and may include, without limitation, risks related to market conditions. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2018 and its other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.*

Investor Contact

Brian Korb  
The Trout Group LLC  
(646) 378-2923  
[bkorb@troutgroup.com](mailto:bkorb@troutgroup.com)

Company Contact

Patrick J. McEnany  
Catalyst Pharmaceuticals  
Chief Executive Officer  
(305) 420-3200  
[pmcenany@catalystpharma.com](mailto:pmcenany@catalystpharma.com)

Media Contacts

David Schull  
Russo Partners  
(212) 845-4271  
[david.schull@russopartnersllc.com](mailto:david.schull@russopartnersllc.com)

###

Page 2